FOLH1 and hepatocellular carcinoma: Moreover, since first-line therapy in locally advanced and metastatic HCC consists of a combination of immunotherapy and anti-neoangiogenic treatment [1], PET/CT with PSMA-radioligands might be a valuable instrument to predict the outcome of the therapy and assess the response to the ongoing treatment.